Current management of chemotherapy-induced neutropenia in adults: key points and new challenges

Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Chenfei Zhou(Ruijin Hospital), Yanhong Deng(Sun Yat-sen University), Yufu Li(Henan Cancer Hospital), Yue-Rong Shuang(Jiangxi Provincial Cancer Hospital), Puyuan Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Wangjun Liao(Sun Yat-sen University), Qinghua Yao(Zhejiang Chinese Medical University), Yanxia Shi(Sun Yat-sen University), Ping Gong(Changchun University of Science and Technology), Sheng Yang(Fujian Medical University), Zuoxing Niu(Shandong Tumor Hospital), Han‐Xiang An(Xiamen University), Zhiguo Luo(Fudan University Shanghai Cancer Center), Ying Cheng(Jilin Province Tumor Hospital), Xin An(Sun Yat-sen University), Li Xiao(Zhongshan Hospital of Xiamen University), Jianping Xiong(Nanchang University), Wensheng Qiu(Qingdao University), Huiqiang Huang(Sun Yat-sen University), Herui Yao(Sun Yat-sen University), Xiaodong Xie(Jiangsu University), Zhi‐Qiang Wang(Nanjing University of Chinese Medicine), Cheng Chen(Kunming Medical University), Li Zhang(Jinan Stomatological Hospital), Xiaohua Wang(Nanjing Medical University), Bo Shen(Jiangsu Cancer Hospital), Jialei Wang(Huaian First People’s Hospital), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Jifeng Feng(Zhejiang Cancer Hospital), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Conghua Xie(Wuhan University), Wenqi Jiang(Shandong Tumor Hospital), Rui‐Hua Xu(Sun Yat-sen University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Gongyan Chen(Harbin Medical University), Jianhua Chang(Shanghai Medical College of Fudan University), Бо Лю(Shanxi Medical University), Jun Zhang(Qingdao University), Xiaotian Zhang(Shanghai University of Traditional Chinese Medicine), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cancer Biology and Medicine
January 1, 2020
10.20892/j.issn.2095-3941.2020.0069
Cited by 95

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k